June 21 (Reuters) – Sanofi SA:
* NEW DATA ON ALTUVIIIO AND FITUSIRAN STRENGTHEN SANOFI’S LEADERSHIP IN THE TREATMENT OF HEMOPHILIA
*THE US FDA AGREED TO REVIEW THE NEW DRUG APPLICATION FOR FITUSIRAN AND IS EXPECTED TO RELEASE ITS DECISION ON MARCH 28, 2025
*INTERMEDIATE RESULTS FROM THE LONG-TERM PHASE 3 STUDY OF
*NEW DATA FROM ATLAS PHASE 3 STUDY STRENGTHENS POTENTIAL OF FITUSIRAN AS A PROPHYLACTIC TREATMENT FOR PEOPLE WITH HEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORS Original text on Workspace: For more details, click ( Gdansk editorial office)
©2024 Thomson Reuters, all rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.